Efficacy and Safety of Efgartigimod in Anti-N-methyl-D-aspartate Receptor Encephalitis: a Phase II Multicenter Single-arm Prospective Pilot Study
This study is a multicenter, open-label, single-arm exploratory trial designed to enroll 20 eligible patients with anti-NMDAR encephalitis. It aims to evaluate the efficacy and safety of efgartigimod in the acute phase of anti-NMDAR encephalitis. The study drug is efgartigimod, α injection administered intravenously at a dose of 10 mg/kg (maximum dose 1200 mg). Each infusion lasts approximately 1 hour, administered weekly for a total of 4 doses. The primary endpoint is the change in modified Rankin Scale (mRS) score at week 4 (day 28) post-treatment compared to baseline.
• Age ≥18 years old, male or female;
• Diagnosed as anti-NMDAR encephalitis, diagnostic criteria as follows:
∙ At least one of the following six major symptoms:
⁃ Abnormal (mental) behavior or cognitive dysfunction
• Speech dysfunction (verbal urgency, hypospeech, mutism)
• Seizures
• Movement disorders, dyskinesias, or postural rigidity/abnormalities
• Decreased level of consciousness
• Autonomic dysfunction or central hypoventilation in the presence of one or more of the six major symptoms;
‣ Positive anti-NMDAR IgG antibody: Diagnosis should be based on CSF antibody positivity using CBA. If only serum samples are available for testing, a positive CBA result must be supplemented with TBA on cultured neurons for definitive confirmation. Serum positivity at low titers (1:10) is not diagnostically significant.
• c.Reasonable exclusion of other etiologies.
• Patients with newly diagnosed or relapsed anti-NMDAR encephalitis who scored ≥2 on the mRS (5 patients each with mRS scores of 2-5);
‣ Newly diagnosed patients must not have received any prior immunosuppressive therapy.
⁃ For relapsed patients:
⁃ For subjects receiving rituximab, treatment must have commenced at least 2 months prior to screening, with the final dose administered no less than 4 weeks before randomization, and no improvement in mRS score within the 4 weeks preceding randomization.
• For subjects receiving other immunosuppressive agents (i.e., mycophenolate mofetil, cyclophosphamide, or azathioprine), treatment must have been ongoing for at least 2 months prior to screening, the dose must have been stable for at least 4 weeks prior to screening, and there must have been no improvement in the mRS score within 4 weeks prior to randomization.
• For subjects receiving oral corticosteroids, those receiving a stable daily dose of ≥20 mg of prednisolone (or its equivalent) with no increase in steroid dosage within 4 weeks prior to screening, and no improvement in mRS score within 4 weeks prior to randomization.
• For subjects receiving repeated courses (pulse therapy) of acute first-line therapy, treatment must be completed \>2 weeks prior to randomization (baseline visit).
• Study subjects had received at least 3 days of glucocorticoid therapy at a dose of 500-1000 mg MP daily within 2 weeks prior to enrollment (baseline visit). They had transitioned to oral corticosteroid therapy and stable doses of non-steroidal immunosuppressive agents (NISIT) (limited to relapsed patients), and had not received IVIG or plasma exchange.
• For women of childbearing potential should use effective contraception during treatment and for at least 3 months after the last dose of Efgartigimod.
• Ability to sign an informed consent form, which includes agreeing to comply with the requirements and restrictions outlined in the informed consent form and this protocol.